Novo Nordisk A/S (NYSE:NVO) Reaches New 52-Week Low After Analyst Downgrade

Novo Nordisk A/S (NYSE:NVO)’s stock price reached a new 52-week low on Monday after Deutsche Bank Aktiengesellschaft downgraded the stock from a buy rating to a hold rating. The company traded as low as $40.01 and last traded at $41.0070, with a volume of 5989976 shares changing hands. The stock had previously closed at $47.42.

NVO has been the topic of a number of other research reports. CICC Research began coverage on shares of Novo Nordisk A/S in a research report on Friday, January 9th. They set an “outperform” rating and a $73.50 target price on the stock. Argus reaffirmed a “hold” rating on shares of Novo Nordisk A/S in a report on Monday, December 8th. Citigroup initiated coverage on shares of Novo Nordisk A/S in a report on Tuesday, January 27th. They issued a “neutral” rating for the company. TD Cowen restated a “buy” rating on shares of Novo Nordisk A/S in a report on Tuesday, February 3rd. Finally, Morgan Stanley reiterated an “underweight” rating and issued a $42.00 price objective on shares of Novo Nordisk A/S in a research note on Wednesday, December 3rd. Seven analysts have rated the stock with a Buy rating, thirteen have given a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $56.07.

Key Novo Nordisk A/S News

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: CagriSema produced meaningful weight loss (reported ~23% in the REDEFINE‑4 open‑label trial), which could still support potential labeling, combination uses, or niche commercial opportunities even though the primary endpoint versus tirzepatide was not met. Novo Nordisk A/S: CagriSema demonstrated 23% weight loss…
• Positive Sentiment: Novo Nordisk remains a cash‑generative leader in diabetes and obesity (Wegovy/Ozempic franchise) with recent quarterly beats and a strong margin profile, which provides balance sheet flexibility to fund R&D and defend market share. 2 Unstoppable Dividend Stocks to Buy Right Now for Less Than $200
• Neutral Sentiment: Some strategists still include NVO in thematic or “vanity” trade lists, reflecting investor interest in large, well‑known GLP‑1 plays despite volatility; this may support episodic buying interest. 2 ‘vanity’ stock picks & 1 crypto play this strategist loves
• Negative Sentiment: Major headline: CagriSema did not achieve non‑inferiority to Lilly’s tirzepatide on weight loss at 84 weeks, triggering a sharp selloff as investors reassess Novo’s competitive outlook in obesity. Novo Nordisk’s next obesity drug falls short of Lilly rival, wiping billions off its market value
• Negative Sentiment: Multiple major outlets report the trial setback and market reaction, noting the plunge erased prior Wegovy-era gains and increases the risk that Lilly will capture a larger share of the obesity market. Novo Nordisk slump wipes out last Wegovy-era gains after trial setback
• Negative Sentiment: Coverage from CNBC and the WSJ highlights the magnitude of the market move and frames this as a key turning point in the GLP‑1 competitive race, which could pressure short‑ and medium‑term growth expectations. Novo Nordisk sinks 10% after weight loss drug fails to match Eli Lilly’s in trial

Institutional Trading of Novo Nordisk A/S

A number of large investors have recently bought and sold shares of the company. Franklin Resources Inc. grew its stake in shares of Novo Nordisk A/S by 4,190.8% during the 3rd quarter. Franklin Resources Inc. now owns 13,984,789 shares of the company’s stock worth $776,016,000 after acquiring an additional 13,658,867 shares during the period. Capital International Investors boosted its position in Novo Nordisk A/S by 52.4% during the third quarter. Capital International Investors now owns 17,713,424 shares of the company’s stock worth $982,969,000 after purchasing an additional 6,092,192 shares during the period. Boston Partners purchased a new position in shares of Novo Nordisk A/S in the third quarter worth about $310,199,000. Price T Rowe Associates Inc. MD raised its position in shares of Novo Nordisk A/S by 99.7% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 9,688,262 shares of the company’s stock valued at $492,940,000 after purchasing an additional 4,836,285 shares during the period. Finally, Voloridge Investment Management LLC lifted its stake in shares of Novo Nordisk A/S by 851.6% during the 4th quarter. Voloridge Investment Management LLC now owns 4,807,279 shares of the company’s stock valued at $244,594,000 after buying an additional 4,302,126 shares in the last quarter. 11.54% of the stock is owned by hedge funds and other institutional investors.

Novo Nordisk A/S Stock Performance

The company’s fifty day moving average is $53.77 and its 200 day moving average is $53.30. The company has a current ratio of 0.80, a quick ratio of 0.57 and a debt-to-equity ratio of 0.61. The company has a market capitalization of $179.94 billion, a P/E ratio of 11.61 and a beta of 0.67.

Novo Nordisk A/S (NYSE:NVO) last posted its earnings results on Tuesday, February 3rd. The company reported $1.01 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.90 by $0.11. The firm had revenue of $12.43 billion for the quarter, compared to the consensus estimate of $11.97 billion. Novo Nordisk A/S had a return on equity of 68.91% and a net margin of 33.03%. As a group, equities analysts anticipate that Novo Nordisk A/S will post 3.84 earnings per share for the current year.

Novo Nordisk A/S Dividend Announcement

The business also recently announced a dividend, which will be paid on Wednesday, April 8th. Shareholders of record on Monday, March 30th will be paid a $1.2751 dividend. The ex-dividend date is Monday, March 30th. This represents a yield of 541.0%. Novo Nordisk A/S’s dividend payout ratio (DPR) is currently 23.63%.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.